Future trends in the development of safer nonsteroidal anti- inflammatory drugs

American Journal of Medicine

Volumn 105, Issue 5 A, 1998, Pages 44S-52S

  Wolfe, M Michael ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; AMPHOLYTE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLOSULIDE; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID; PIROXICAM; PLACEBO; ROFECOXIB; SULINDAC; TREFOIL PEPTIDE; UNCLASSIFIED DRUG;

ARTHRITIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; PRIORITY JOURNAL;

EID: 0032476648     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00281-2     Document Type: Conference Paper

References (68)

1. Agrawal N.M., Roth S., Graham D.Y., et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med. 115:1991;195-200.
2. Graham D.Y., Agrawal N.M., Roth S.H. Prevention of NSAID-induced gastric ulcer with misoprostol multicentre, double-blind, placebo-controlled trial . Lancet. ii:1988;1277-1280.
3. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 123:1995;241-249.
4. Verdickt W., Moran C., Hantzschel H., et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol. 21:1992;85-91.
5. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 338:1998;719-726.
6. Hawkey C.J., Karrasch J.A., Szczepanski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 338:1998;727-734.
7. Feldman M. Southwestern Internal Medicine Conference Prostaglandins and gastric ulcers: from seminal vesicle to misoprostol (Cytotec ) . Am J Med Sci. 300:1990;116-132.
8. Lanza F.L., Aspinall R.L., Swabb E.A., et al. Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology. 95:1988;289-294.
9. Jiranek G.C., Kimmey M.B., Saunders D.R., et al. Misoprostol reduces gastroduodenal injury from one week of aspirin an endoscopic study . Gastroenterology. 96:1989;656-661.
10. Vane J. Towards a better aspirin. Nature. 367:1994;215-216.
11. Vane J.R., Botting R.M. The history of anti-inflammatory drugs and their mechanism of action. Bazan N., Botting J., Vane J. New Targets in Inflammation Inhibitors of COX-2 or Adhesion Molecules . 1996;1-12 Kluwer Academic Publishers, Dordrecht.
12. Henry D., Lim L.L.-Y., García Rodríguez L.A., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs results of a collaborative meta-analysis . BMJ. 312:1996;1563-1566.
13. Pairet M., Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. Vane J., Botting J., Botting R. Improved Non-Steroid Anti-Inflammatory Drugs COX-2 Enzyme Inhibitors . 1996;103-119 Kluwer Academic Publishers, Dordrecht.
14. Pairet M., van Ryn J., Mauz A., et al. Differential inhibition of COX-1 and COX-2 by NSAIDs a summary of results obtained using various test systems . Vane J., Botting J. Selective COX-2 Inhibitors Pharmacology, Clinical Effects and Therapeutic Potential . 1998;27-46 Kluwer Academic Publishers, Dordrecht.
15. Mitchell J.A., Akarasereenont P., Thiemermann C., et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 90:1993;11693-11697.
16. Akarasereenont P., Mitchell J.A., Thiemermann C., Vane J.R. Relative potency of nonsteroid anti-inflammatory drugs as inhibitors of cyclooxygenase-1 or cyclooxygenase-2. (Abstr.) Br J Pharmacol. 112:(suppl):1994;183P.
17. Hubbard R.C., Koepp R., Yu S.S., et al. Pilot efficacy of SC-58635, a COX-2-selective inhibitor, in rheumatoid arthritis. (Abstr.) Arthritis Rheum. 40:(suppl):1997;S51.
18. Ehrich E., Schnitzer T., Kivitz A., et al. MK-966, a highly selective COX-2 inhibitor was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study. (Abstr.) Arthritis Rheum. 40:(suppl):1997;S85.
19. Lanza F.L., Rack M.F., Callison D.A., et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2-selective inhibitor. (Abstr.) Gastroenterology. 112:(suppl):1997;A194.
20. Lanza F., Simon T., Quan H., et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg q.d.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg q.i.d or ibuprofen (IBU) 800 mg t.i.d. (Abstr.) Gastroenterology. 112:(suppl):1997;A194.
21. Dinchuk J.E., Car B.D., Focht R.J., et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 378:1995;406-409.
22. Morham S.G., Langenbach R., Loftin C.D., et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 83:1995;473-482.
23. Kömhoff M., Gröne H.-J., Klein T., et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney implication for renal function . Am J Physiol. 272:1997;F460-F468.
24. Chakraborty I., Das S.K., Wang J., Dey S.K. Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol. 16:1996;107-122.
25. Lim H., Paria B.C., Das S.K., et al. Multiple female reproductive failures in cyclooxygenase 2 deficient mice. Cell. 91:1997;197-208.
26. Emery P. Pharmacology, safety data and therapeutics of COX-2 inhibitors. Vane J., Botting J., Botting R. Improved Non-Steroid Anti-Inflammatory Drugs COX-2 Enzyme Inhibitors . 1996;229-241 Kluwer Academic Publishers, Dordrecht.
27. Glaser K., Sung M.-L., O'Neill K., et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol. 281:1995;107-111.
28. Laneuville O., Breuer D.K., Dewitt D.L., et al. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 271:1994;927-934.
29. Adams L., Neuman R.G., Sachs J., Bralow S.P. Efficacy and gastric safety of etodolac as determined in cultured human gastric and synovial cells. (Abstr.) Gastroenterology. 98:(suppl):1990;A14.
30. Meade E.A., Smith W.L., DeWitt D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 268:1993;6610-6614.
31. Lanza F., Rack M.F., Lynn M., et al. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol. 14:1987;338-341.
32. Bianchi Porro G., Caruso I., Petrillo M., et al. A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients. J Intern Med. 229:1991;5-8.
33. Laine L., Sloane R., Ferretti M., Cominelli F. A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc. 42:1995;428-433.
34. Lipani J.A., Poland M. Clinical update of the relative safety of nabumetone in long-term clinical trials. Inflammopharmacology. 3:1995;351-361.
35. Churchill L., Graham A.G., Shih C.-K., et al. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology. 4:1996;125-135.
36. Patrignani P., Panara M.R., Santini G., et al. Differential inhibition of the cyclooxygenase activity of prostaglandin endoperoxide synthase isozymes in vitro and ex vivo in man. (Abstr.) Prostaglandins Leukot Essent Fatty Acids. 55:(suppl 1):1996;P115.
37. Young J.M., Panah S., Satchawatcharaphong C., Cheung P.S. Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res. 45:1996;246-253.
38. Riendeau D., Percival M.D., Boyce S., et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 121:1997;105-117.
39. Cipollone F., Ganci A., Panara M.R., et al. Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther. 58:1995;335-341.
40. Pairet M., Churchill L., Engelhardt G. Differential inhibition of cyclooxygenases 1 and 2 by NSAIDs. Bazan N., Botting J., Vane J. New Targets in Inflammation Inhibitors of COX-2 or Adhesion Molecules . 1996;23-38 Kluwer Academic Publishers, Dordrecht.
41. Pairet M, Bögel R, Erni I, et al. Tissue selective inhibition of prostaglandin synthesis by NSAIDs. (Abstr.) Paper presented at: XIX ILAR Congress of Rheumatology; June 8-13, 1997;Singapore.
42. Stichtenoth D.O., Wagner B., Frölich J.C. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Investig Med. 45:1997;44-49.
43. Distel M., Mueller C., Bluhmki E., Fries J. Safety of meloxicam a global analysis of clinical trials . Br J Rheumatol. 35:(suppl 1):1996;68-77.
44. Distel M., Mueller C., Bluhmki E. Global analysis of gastrointestinal safety of a new NSAID, meloxicam. Inflammopharmacology. 4:1996;71-81.
45. Furst D. Meloxicam selective COX-2 inhibition in clinical practice . Semin Arthritis Rheum. 26:(suppl 1):1997;21-27.
46. Patoia L., Santucci L., Furno P., et al. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol. 35:(suppl 1):1996;61-67.
47. Wallace J.L. Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide. Clin Invest Med. 19:1996;346-351.
48. Del Soldato P., Cuzzolin L., Adami A., et al. Nitric oxide-releasing NSAIDs, a novel class of safe and effective anti-inflammatory agents. Inflammopharmacology. 4:1996;181-188.
49. Wallace J.L., Reuter B., Cicala C., et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 107:1994;173-179.
50. Mitchell J., Cirino G., Akarasereenont P., et al. Flurbinitroxybutylester a novel anti-inflammatory drug devoid of ulcerogenic activity, inhibits cyclo-oxygenase-1 and cyclo-oxygenase-2 . (Abstr.) Can J Physiol Pharmacol. 72:1994;270.
51. Davies N.M., R seth A.G., Appleyard C.B., et al. NO-naproxen vs naproxen ulcerogenic, analgesic and anti-inflammatory effects . Aliment Pharmacol Ther. 11:1997;69-79.
52. Cirino G., Wheeler-Jones C.P.D., Wallace J.L., et al. Inhibition of inducible nitric oxide synthase expression by novel nonsteroidal anti-inflammatory derivatives with gastrointestinal-sparing properties. Br J Pharmacol. 117:1996;1421-1426.
53. Elliott S.N., McKnight W., Cirino G., Wallace J.L. A nitric oxide releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 109:1995;524-530.
54. Konturek S., Brzozowski T., Majka J., et al. Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers. Eur J Pharmacol. 239:1993;215-217.
55. Saha J.K., Thomas G., Marek P., et al. Nitrosothiol protects against acute and subchronic gastric mucosal damage induced by piroxicam in rats. (Abstr.) Gastroenterology. 112:(suppl):1997;A399.
56. Lichtenberger L.M., Wang Z.-M., Romero J.J., et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids insight into the mechanism and reversal of NSAID-induced gastrointestinal injury . Nat Med. 1:1995;154-158.
57. Lichtenberger L.M., Ulloa C., Romero J.J., et al. Nonsteroidal anti-inflammatory drug and phospholipid prodrugs combination therapy with antisecretory agents in rats . Gastroenterology. 111:1996;990-995.
58. Lichtenberger L.M., Ulloa C., Vanous A.L., et al. Zwitterionic phospholipids enhance aspirin's therapeutic activity, as demonstrated in rodent model systems. J Pharmacol Exp Ther. 277:1996;1221-1227.
59. Giraud M.N., Sanduja S.K., Felder T.B., et al. Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats. Aliment Pharmacol Ther. 11:1997;899-906.
60. Carabaza A., Cabre F., Rotllan E., et al. Stereoselective inhibition of inducible cylooxygenase by chiral nonsteroidal antiinflammatory drugs. J Clin Pharmacol. 36:1996;505-512.
61. Davies N.M., Wright M.R., Russell A.S., Jamali F. Effect of the enantiomers of flurbiprofen, ibuprofen, and ketoprofen on intestinal permeability. J Pharm Sci. 85:1996;1170-1173.
62. Jorgensen K.H., Thim L., Jacobsen H.E. Pancreatic spasmolytic polypeptide (PSP) I. Preparation and initial chemical characterization of a new polypeptide from porcine pancreas . Regul Pept. 3:1982;207-219.
63. Carr M.D., Bauer C.J., Gradwell M.J., Feeney J. Solution structure of a trefoil-motif-containing cell growth factor, porcine spasmolytic protein. Proc Natl Acad Sci USA. 91:1994;2206-2210.
64. Hanby A.M., Poulsom R., Elia G., et al. The expression of the trefoil peptide pS2 and human spasmolytic polypeptide (hSP) in gastric metaplasia of the proximal duodenum implications for the nature of gastric metaplasia . J Pathol. 169:1993;355-360.
65. Wright N.A., Poulsom R., Stamp G.W., et al. Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues. J Pathol. 162:1990;279-284.
66. Mashimo H., Wu D.-C., Podolsky D.K., Fishman M.C. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science. 274:1996;262-265.
67. Playford R.J., Marchbank T., Goodlad R.A., et al. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci USA. 93:1996;2137-2142.
68. Babyatsky M.W., deBeaumont M., Thim L., Podolsky D.K. Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology. 110:1996;489-497.